317 related articles for article (PubMed ID: 24310792)
1. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
Homma Y; Taniguchi K; Murakami T; Nakagawa K; Nakazawa M; Matsuyama R; Mori R; Takeda K; Ueda M; Ichikawa Y; Tanaka K; Endo I
Ann Surg Oncol; 2014 Feb; 21(2):670-6. PubMed ID: 24310792
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
Motoi F; Ishida K; Fujishima F; Ottomo S; Oikawa M; Okada T; Shimamura H; Takemura S; Ono F; Akada M; Nakagawa K; Katayose Y; Egawa S; Unno M
Ann Surg Oncol; 2013 Nov; 20(12):3794-801. PubMed ID: 23838925
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Nagakawa Y; Hosokawa Y; Nakayama H; Sahara Y; Takishita C; Nakajima T; Hijikata Y; Kasuya K; Katsumata K; Tokuuye K; Tsuchida A
Cancer Chemother Pharmacol; 2017 May; 79(5):951-957. PubMed ID: 28378027
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
Satoi S; Yanagimoto H; Yamamoto T; Ohe C; Miyasaka C; Uemura Y; Hirooka S; Yamaki S; Ryota H; Michiura T; Inoue K; Matsui Y; Tanigawa N; Kon M
Surg Today; 2017 Jan; 47(1):84-91. PubMed ID: 27262676
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
[TBL] [Abstract][Full Text] [Related]
6. MZB1 in borderline resectable pancreatic cancer resected after neoadjuvant chemoradiotherapy.
Miyake K; Mori R; Homma Y; Matsuyama R; Okayama A; Murakami T; Hirano H; Endo I
J Surg Res; 2017 Dec; 220():391-401. PubMed ID: 29180208
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.
Kubo H; Murakami T; Matsuyama R; Yabushita Y; Tsuchiya N; Sawada Y; Homma Y; Kumamoto T; Endo I
World J Surg; 2019 Dec; 43(12):3153-3160. PubMed ID: 31549202
[TBL] [Abstract][Full Text] [Related]
8. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
Amano R; Kimura K; Nakata B; Yamazoe S; Motomura H; Yamamoto A; Tanaka S; Hirakawa K
Surgery; 2015 Jul; 158(1):191-200. PubMed ID: 25900035
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility complex class I-related chain A/B expression.
Murakami T; Homma Y; Matsuyama R; Mori R; Miyake K; Tanaka Y; Den K; Nagashima Y; Nakazawa M; Hiroshima Y; Ueda M; Tanaka K; Hoffman RM; Bouvet M; Endo I
J Surg Oncol; 2017 Sep; 116(3):416-426. PubMed ID: 28608409
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
Endo Y; Kitago M; Aiura K; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Nakano Y; Itano O; Fukada J; Masugi Y; Kitagawa Y
World J Surg Oncol; 2019 Aug; 17(1):145. PubMed ID: 31420046
[TBL] [Abstract][Full Text] [Related]
12. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.
Tzeng CW; Fleming JB; Lee JE; Xiao L; Pisters PW; Vauthey JN; Abdalla EK; Wolff RA; Varadhachary GR; Fogelman DR; Crane CH; Balachandran A; Katz MH
Ann Surg Oncol; 2012 Jun; 19(6):2045-53. PubMed ID: 22258816
[TBL] [Abstract][Full Text] [Related]
13. The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer.
Okubo S; Suzuki T; Hioki M; Shimizu Y; Toyama H; Morinaga S; Gotohda N; Uesaka K; Ishii G; Takahashi S; Kojima M
Cancer Sci; 2021 Jul; 112(7):2895-2904. PubMed ID: 33931909
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer.
Cooper AB; Slack R; Fogelman D; Holmes HM; Petzel M; Parker N; Balachandran A; Garg N; Ngo-Huang A; Varadhachary G; Evans DB; Lee JE; Aloia T; Conrad C; Vauthey JN; Fleming JB; Katz MH
Ann Surg Oncol; 2015 Jul; 22(7):2416-23. PubMed ID: 25519927
[TBL] [Abstract][Full Text] [Related]
15. Reduction of gender-associated M2-like tumor-associated macrophages in the tumor microenvironment of patients with pancreatic cancer after neoadjuvant chemoradiotherapy.
Matsuki H; Hiroshima Y; Miyake K; Murakami T; Homma Y; Matsuyama R; Morioka D; Kurotaki D; Tamura T; Endo I
J Hepatobiliary Pancreat Sci; 2021 Feb; 28(2):174-182. PubMed ID: 33316125
[TBL] [Abstract][Full Text] [Related]
16. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS
Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973
[TBL] [Abstract][Full Text] [Related]
17. Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer.
Satoi S; Toyokawa H; Yanagimoto H; Yamamoto T; Kamata M; Ohe C; Sakaida N; Uemura Y; Kitade H; Tanigawa N; Inoue K; Matsui Y; Kwon AH
J Gastrointest Surg; 2012 Apr; 16(4):784-92. PubMed ID: 22160780
[TBL] [Abstract][Full Text] [Related]
18. [Neoadjuvant Chemotherapy Using S-1 for Pancreatic Cancer - Mid-Term Results].
Homma Y; Honda G; Sakamoto K; Kurata M; Honjo M; Hirata Y; Shinya S
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1166-1170. PubMed ID: 27760934
[TBL] [Abstract][Full Text] [Related]
19. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
[TBL] [Abstract][Full Text] [Related]
20. Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer.
Yabushita Y; Mori R; Taniguchi K; Matsuyama R; Kumamoto T; Sakamaki K; Kubota K; Endo I
Anticancer Res; 2017 May; 37(5):2465-2476. PubMed ID: 28476815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]